Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038739 · ClinicalTrials.gov registry record · Phase 3
Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis
A Phase 3 study, sponsored by Dr. Falk Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT01038739 is a Phase 3 study that was terminated before completion, run by Dr. Falk Pharma. The registered enrollment target is 330 participants.
The verdict
NCT01038739, a Phase 3 study, was terminated before completion, sponsored by Dr. Falk Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
The purpose of the study is to determine which dose of mesalazine granules compared to placebo is more effective in the prevention of recurrence of disease.
Interventions
- DRUG Placebo
- DRUG Mesalazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01038739
The ClinicalTrials.gov registry entry for NCT01038739 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dr. Falk Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01038739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01038739 about?
NCT01038739 is a clinical study titled "Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis". The purpose of the study is to determine which dose of mesalazine granules compared to placebo is more effective in the prevention of recurrence of disease.
What is the current status of trial NCT01038739?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2010-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01038739?
The interventions under investigation include: Placebo (DRUG), Mesalazine (DRUG).
Who is sponsoring clinical trial NCT01038739?
This trial is sponsored by Dr. Falk Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.